Extended Data Fig. 6: Confounding between therapy areas and properties of supporting genetic evidence.
From: Refining the impact of genetic evidence on clinical success
In panels A-E, each point represents one GWAS Catalog-supported T-I pair in phase I through launched, and boxes represent medians and interquartile ranges (25th, 50th, and 75th percentile). Each panel A-E represents the cross-tabulation of therapy areas versus the properties examined in Fig. 1d. Kruskal-Wallis tests treat each variable as continuous, while chi-squared tests are applied to the discrete bins used in Fig. 1d. A) Year of discovery, Kruskal-Wallis P = 1.1e-11, chi-squared P = 2.9e-16, N = 686 target-indication-area (T-I-A) triplets; B) gene count, Kruskal-Wallis P = 6.2e-35, chi-squared P = 7.1e-47, N = 770 T-I-A triplets; C) absolute beta, Kruskal-Wallis P = 1.2e-5, chi-squared P = 1.7e-7, N = 461 T-I-A triplets; D) absolute odds ratio, Kruskal-Wallis P = 2.5e-5, chi-squared P = 4.3e-6, N = 305 T-I-A triplets; E) minor allele frequency, Kruskal-Wallis P = 5.7e-4, chi-squared P = 4.3e-3, N = 584 T-I-A triplets; F) Barplot of therapy areas of genetically supported T-I by source of GWAS data within OTG, chi-squared P = 2.4e-7. See Fig. S7 for the same analyses restricted to drugs with a single known target.